$-0.62
(Market cap
$13,355 Mln
Revenue (TTM)
$2,375 Mln
P/E Ratio
17.6
P/B Ratio
6.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
12.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$3
-
Face value
--
-
Shares outstanding
251,355,083
10 Years Aggregate
CFO
$3,591.92 Mln
EBITDA
$2,393.43 Mln
Net Profit
$2,144.59 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Exelixis (EXEL)
| 18.2 | 3.4 | 23.9 | 25.3 | 39.5 | 18.6 | 21.2 |
|
BSE Sensex
| -8.6 | 2.9 | 1.8 | -5.1 | 6.9 | 8.1 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Exelixis (EXEL)
| 31.6 | 38.4 | 49.6 | -12.3 | -8.9 | 13.9 | -10.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Exelixis (EXEL)
|
51.8 | 13,354.5 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.6 | 6.9 |
| 277.0 | 37,764.0 | 4,286.9 | 577.2 | 20.3 | 88.2 | 70.9 | 35.1 | |
| 230.9 | 14,299.5 | 867.5 | 506.6 | -0.6 | -- | 25 | 25.4 | |
| 131.3 | 17,452.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 167.7 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 504.7 | 11,084.5 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 20.4 | |
| 459.3 | 13,347.1 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29.4 | 22.3 | |
| 603.4 | 64,176.2 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 540.6 | 23,174.2 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.2 | 3.9 | |
| 451.8 | 112,924.4 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.4 | 5.8 |
Shareholding Pattern
View DetailsAbout Exelixis (EXEL)
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced... renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Read more
-
Co-Founder & Chair of the Board
Dr. Stelios Papadopoulos Ph.D.
-
Co-Founder & Chair of the Board
Dr. Stelios Papadopoulos Ph.D.
-
Headquarters
Alameda, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Exelixis (EXEL)
What is the current share price of Exelixis Inc (EXEL) Today?
The share price of Exelixis Inc (EXEL) is $51.82 (NASDAQ) as of 18-Jun-2026 15:40 EDT. Exelixis Inc (EXEL) has given a return of 39.5% in the last 3 years.
What is the current PB & PE ratio of Exelixis Inc (EXEL)?
The P/E ratio of Exelixis Inc (EXEL) is 17.59 times as on 12-Jun-2026.
The P/B ratio of Exelixis Inc (EXEL) is 6.90 times as on 12-Jun-2026, a 67 premium to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
15.79
|
5.72
|
|
2024
|
18.00
|
4.18
|
|
2023
|
36.14
|
3.32
|
|
2022
|
28.45
|
2.08
|
|
2022
|
--
|
--
|
What is the 52 Week High and Low of Exelixis Inc (EXEL)?
The 52-week high and low of Exelixis Inc (EXEL) are Rs 53.93 and Rs 33.76 as of 19-Jun-2026.
What is the market cap of Exelixis Inc (EXEL)?
Exelixis Inc (EXEL) has a market capitalisation of $ 13,355 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Exelixis Inc (EXEL)?
Before investing in Exelixis Inc (EXEL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.